Variability in Humoral Immunity to Measles Vaccine: New Developments

Trends in Molecular Medicine

Volumn 21, Issue 12, 2015, Pages 789-801

  Haralambieva, Iana H ^a   Kennedy, Richard B ^a   Ovsyannikova, Inna G ^a   Whitaker, Jennifer A ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HLA DQA1 ANTIGEN; MEASLES ANTIBODY; MEASLES VACCINE; NEUTRALIZING ANTIBODY; HLA ANTIGEN;

3' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; BIOINFORMATICS; CELLULAR IMMUNITY; DEVELOPED COUNTRY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; EUROPE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERMANY; GOLD STANDARD; HAPLOTYPE; HEREDITY; HISTOCOMPATIBILITY; HLA SYSTEM; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; ITALY; MEASLES; MEASLES VACCINATION; MOLECULAR BIOLOGY; PREVENTIVE HEALTH SERVICE; REVIEW; SPAIN; UNITED STATES; VACCINATION; VACCINE FAILURE; VIRUS NEUTRALIZATION; GENETIC ASSOCIATION STUDY; HUMAN; IMMUNOLOGY;

DEVELOPED COUNTRIES; GENETIC ASSOCIATION STUDIES; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; MEASLES VACCINE; VACCINATION;

EID: 84949625327     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.10.005     Document Type: Review

References (97)

1. Global progress towards regional measles elimination, worldwide, 2000-2013. Wkly. Epidemiol. Rec. 2014, 89:509-516. WHO.
2. Whitaker J.A., Poland G.A. Measles and mumps outbreaks in the United States: Think globally, vaccinate locally. Vaccine 2014, 32:4703-4704.
3. Haralambieva I.H., et al. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev. Vaccines 2013, 12:57-70.
4. Poland G.A., Jacobson R.M. The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines?. Vaccine 2012, 30:103-104.
5. Clemmons N.S., et al. Measles - United States, January 4-April, 2, 2015. MMWR Morb. Mortal. Wkly. Rep. 2015, 64:373-376.
6. Rosen J.B., et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin. Infect. Dis. 2014, 58:1205-1210.
7. Defay F., et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics 2013, 132:e1126-e1133.
8. De Serres G., et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin. Infect. Dis. 2012, 55:394-402.
9. Zipprich J., et al. Measles outbreak - California, December 2014-February 2015. MMWR Morb. Mortal. Wkly. Rep. 2015, 64:153-154.
10. Strebel P., et al. Measles Vaccine. Vaccines 2013, 352-387. Elsevier. 6th Edn. S.A. Plotkin (Ed.).
11. Haralambieva I.H., et al. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 2011, 29:4485-4491.
12. Poland G.A., Jacobson R.M. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. Arch. Intern. Med. 1994, 154:1815-1820.
13. Bouche F.B., et al. Neutralizing B cell response in measles. Viral Immunol. 2002, 15:451-471.
14. Haralambieva I.H., et al. Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles immunity. Clin. Vaccine Immunol. 2008, 15:1054-1059.
15. Plotkin S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010, 17:1055-1065.
16. de Swart R.L., et al. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J. Virol. 2005, 79:11547-11551.
17. de Swart R.L., et al. Depletion of measles virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing antibodies. J. Gen. Virol. 2009, 90:2982-2989.
18. Samb B., et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 1995, 14:203-209.
19. Jacobson R.M., et al. Independence of measles-specific humoral and cellular immune responses to vaccination. Hum. Immunol. 2012, 73:474-479.
20. Poland G.A., et al. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther. 2007, 82:653-664.
21. Poland G.A., et al. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS 2011, 15:625-636.
22. Poland G.A., et al. Vaccinomics and personalized vaccinology: Is science leading us toward a new path of directed vaccine development and discovery?. PLoS Pathog. 2011, 7:e1002344.
23. Tan P.L., et al. Twin studies of immunogenicity - determining the genetic contribution to vaccine failure. Vaccine 2001, 19:2434-2439.
24. Jacobson R.M., et al. Studies of twins in vaccinology. Vaccine 2007, 25:3160-3164.
25. Ovsyannikova I.G., et al. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 2009, 27:6926-6931.
26. Poland G.A., et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001, 20:430-438.
27. Ovsyannikova I.G., et al. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 2004, 22:1914-1920.
28. Ovsyannikova I.G., et al. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J. Infect. Dis. 2006, 193:655-663.
29. Ovsyannikova I.G., et al. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 2007, 25:3090-3100.
30. Ovsyannikova I.G., et al. Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine 2012, 30:2146-2152.
31. Jacobson R.M., et al. Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: persistence, dampening, and extinction of associations found after a first dose. Vaccine 2011, 29:7982-7991.
32. Ovsyannikova I.G., et al. Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. PLoS ONE 2010, 5:e11806.
33. Ovsyannikova I.G., et al. Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood. Virology 2003, 312:495-506.
34. Ovsyannikova I.G., et al. Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides. J. Virol. 2004, 78:42-51.
35. Poland G.A., et al. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009, 10:837-852.
36. Kennedy R.B., et al. Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. Vaccine 2012, 30:2159-2167.
37. Dhiman N., et al. Associations between measles vaccine immunity and single nucleotide polymorphisms in cytokine and cytokine receptor genes. J. Infect. Dis. 2007, 195:21-29.
38. Dhiman N., et al. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J. Allergy Clin. Immunol. 2007, 120:666-672.
39. Ovsyannikova I.G., et al. Effects of vitamin A and D receptor gene polymophisms/haplotypes on immune responses to measles vaccine. Pharmacogenet. Genomics 2012, 22:20-31.
40. Ovsyannikova I.G., et al. The association of CD46, SLAM, and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses - a replication study and examination of novel polymorphisms. Hum. Heredity 2011, 72:206-223.
41. Haralambieva I.H., et al. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 2011, 29:8988-8997.
42. Haralambieva I.H., et al. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 2011, 29:7883-7895.
43. Yoo K.H., et al. Assessment of humoral and cell-mediated immune response to measles-mumps-rubella vaccine viruses among patients with asthma. Allergy Asthma Proc. 2010, 31:499-506.
44. Dhiman N., et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008, 26:1731-1736.
45. Poland G.A., et al. Genetics and immune response to vaccines. Genetic Susceptibility to Infectious Diseases 2008, 1-447. Oxford University Press. R.A. Kaslow (Ed.).
46. Clifford H.D., et al. TLR3 and RIG-I gene variants: associations with functional effects on receptor expression and responses to measles virus and vaccine in vaccinated infants. Hum. Immunol. 2012, 73:677-685.
47. Clifford H.D., et al. CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children. Clin. Vaccine Immunol. 2012, 19:704-710.
48. Clifford H.D., et al. Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine. Immunogenetics 2012, 64:219-228.
49. Clifford H.D., et al. SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine. Vaccine 2011, 29:5407-5413.
50. Newport M.J. The genetic regulation of infant immune responses to vaccination. Front. Immunol. 2015, 6:18.
51. Clifford H.D., et al. Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine 2012, 30:6180-6185.
52. Feenstra B., et al. Common variants associated with general and MMR vaccine-related febrile seizures. Nat. Genet. 2014, 46:1274-1282.
53. Lappalainen T., et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 2013, 501:506-511.
54. Muhlebach M.D., et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011, 480:530-533.
55. Noyce R.S., et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011, 7:e1002240.
56. Seegers D., et al. A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun. 2002, 3:419-423.
57. Yucesoy B., et al. Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine 2009, 27:6991-6997.
58. Ovsyannikova I.G., et al. Single-nucleotide polymorphism associations in common with immune responses to measles and rubella vaccines. Immunogenetics 2014, 66:663-669.
59. Lambert N.D., et al. Polymorphisms in HLA-DPB1 are associated with differences in rubella-specific humoral immunity after vaccination. J. Infect. Dis. 2015, 211:898-905.
60. Kennedy R.B., et al. Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Hum. Genet. 2012, 131:1433-1451.
61. Ovsyannikova I.G., et al. Genome-wide association study of antibody response to smallpox vaccine. Vaccine 2012, 30:4182-4189.
62. Oberg A.L., et al. Systems biology approaches to new vaccine development. Curr. Opin. Immunol. 2011, 23:436-443.
63. Kennedy R.B., Poland G.A. The top five 'game changers' in vaccinology: toward rational and directed vaccine development. OMICS 2011, 15:533-537.
64. Oberg A.L., et al. Lessons learned in the analysis of high-dimensional data in vaccinomics. Vaccine 2015, 33:5262-5270.
65. Sharma D., et al. Unraveling the web of viroinformatics: computational tools and databases in virus research. J. Virol. 2015, 89:1489-1501.
66. He L., Zhu J. Computational tools for epitope vaccine design and evaluation. Curr. Opin. Virol. 2015, 11:103-112.
67. Paquet E., Viktor H.L. Molecular dynamics, monte carlo simulations, and langevin dynamics: a computational review. Biomed. Res. Int. 2015, 2015:183918.
68. Lee P.S., Wilson I.A. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 2015, 386:323-341.
69. Correia B.E., et al. Proof of principle for epitope-focused vaccine design. Nature 2014, 507:201-206.
70. + T cell phenotypes. Immunity 2012, 36:142-152.
71. Newell E.W., et al. Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat. Biotechnol. 2013, 31:623-629.
72. Han A., et al. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat. Biotechnol. 2014, 32:684-692.
73. Shalek A.K., et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 2013, 498:236-240.
74. Shalek A.K., et al. Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature 2014, 510:363-369.
75. Poland G.A., et al. Vaccinomics, adversomics, and the immune response network theory: Individualized vaccinology in the 21st century. Semin. Immunol. 2013, 25:89-103.
76. Pulendran B., et al. Systems vaccinology. Immunity 2010, 33:516-529.
77. Querec T.D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009, 10:116-125.
78. Nakaya H.I., et al. Systems biology of seasonal influenza vaccination in humans. Nat. Immunol. 2011, 12:786-795.
79. Obermoser G., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013, 38:831-844.
80. Teunissen M.B., et al. Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design. Curr. Top. Microbiol. Immunol. 2012, 351:25-76.
81. Low N., et al. A randomized, controlled trial of an aerosolized vaccine against measles. N. Engl. J. Med. 2015, 372:1519-1529.
82. Mayor S. Inhaled measles vaccine is less protective than injected vaccine, study shows. BMJ 2015, 350:h2006.
83. Edens C., et al. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine 2015, 33:4712-4718.
84. Pe'er I., et al. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet. Epidemiol. 2008, 32:381-385.
85. Wacholder S., et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 2004, 96:434-442.
86. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:9440-9445.
87. Gans H., et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J. Infect. Dis. 2001, 184:817-826.
88. Gans H.A., et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J. Infect. Dis. 2004, 190:83-90.
89. LeBaron C.W., et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch. Pediatr. Adolesc. Med. 2007, 161:294-301.
90. Davidkin I., et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J. Infect. Dis. 2008, 197:950-956.
91. Kakoulidou M., et al. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults. Vaccine 2013, 31:711-717.
92. Ovsyannikova I.G., et al. Associations between polymorphisms in the antiviral TRIM genes and measles vaccine immunity. Hum. Immunol. 2013, 74:768-774.
93. Jacobsen M., et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J. Mol. Med. 2007, 85:613-621.
94. Lambert N.D., et al. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev. Vaccines 2012, 11:985-994.
95. Haralambieva I.H., et al. Profiling of measles-dpecific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays. Viruses 2015, 7:1113-1133.
96. Bian X., et al. Antiviral antibody profiling by high-density protein arrays. Proteomics 2015, 15:2136-2145.
97. de Vries R.D., et al. Measles immune suppression: lessons from the macaque model. PLoS Pathog. 2012, 8:e1002885.